Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer
Status:
Suspended
Trial end date:
2025-01-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well tazemetostat works in treating patients with ovarian or
endometrial cancer that has come back (recurrent). Chemotherapy drugs, such as tazemetostat,
work in different ways to stop the growth of tumor cells, either by killing the cells, by
stopping them from dividing, or by stopping them from spreading.